Open AccessVaginal Swabs Are the Specimens of Choice When Screening for Chlamydia trachomatis and Neisseria gonorrhoeae: Results From a Multicenter Evaluation of the APTIMA Assays for Both Infections
Author(s) -
Julius Schachter,
Max Chernesky,
Dean Willis,
Paul Fine,
David H. Martín,
D. Fuller,
Jeanne A. Jordan,
William M. Janda,
Edward W. Hook
Publication year - 2005
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/01.olq.0000190092.59482.96
Subject(s) - chlamydia trachomatis , medicine , neisseria gonorrhoeae , gynecology , concordance , chlamydia , vaginal discharge , sexually transmitted disease , obstetrics , virology , microbiology and biotechnology , syphilis , immunology , biology , human immunodeficiency virus (hiv)
Vaginal swabs were recently U.S. Food and Drug Administration-cleared for detecting Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) using Gen-Probe Incorporated's APTIMA COMBO2 Assay (AC2). We assessed the APTIMA CT Assay (ACT) for CT, APTIMA GC Assay (AGC) for GC, and AC2 for both organisms using patient- and clinician-collected vaginal swabs.